Lexaria’s DehydraTECH Technology Improves Performance of GLP-1 drug, Rybelsus®

Lexaria Bioscience (Nasdaq: LEXX) has demonstrated that its DehydraTECH technology improves the performance of GLP-1 drug, semaglutide, in a human pilot study. DehydraTECH-powered semaglutide achieved sustained higher levels of semaglutide in subjects’ blood, faster achievement of peak drug delivery and reduced side effects. The company’s share price rose 25% in morning trading following the news….